VM
Adocia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BioChaperone® Lispro (THDB0206) | Type 1 Diabetes | Phase 3 |
| BioChaperone® Lispro | Type 2 Diabetes | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Type 2 Diabetes | Phase 2 |
| BioChaperone® Glucagon | Hypoglycemia | Phase 1 |
| AdOral® Insulin | Diabetes | Preclinical |
| AdoShell® Islet Cell Therapy | Type 1 Diabetes | Preclinical |
| AdoXLong Platform | Diabetes & Obesity | Discovery |
Leadership Team at Adocia
OS
Olivier Soula
Chief Executive Officer, Co-founder
MG
Mathieu-William Gilbert
Chief Financial Officer - Chief Operating Officer
JB
Jérémy Benattar
Marketing & Strategy Director
MG
Martin Gaudier
Research & Development Director
YP
You Ping Chan
Research & Development Director
ED
Emmanuel Dauty
Innovation & Physico Chemistry Department Director
DR
David Rigal
Pharmaceutical Operations Director
GF
Géraldine Favre Soula
Director of human resources
SB
Stéphane Boissel
Chairman of the Board
MD
Mads Dall
Board member